Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Canevari

Showing results (111-120 of 131) with videos related to

Pageof 14
Sort By:
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
Radioimmunoscintigraphy of ovarian cancer with the MOv18 monoclonal antibodyF Crippa, G L Buraggi, E Di Re, et al.
Hybridoma|August 1, 1992
Production and characterization of a monoclonal antibody against the ribosome inactivating protein alpha sarcinA J Ferreri, E Ferraris di Celle, M Caldera, et al.
British Journal of Cancer|December 17, 2013
Monitoring response to cytostatic cisplatin in a HER2(+) ovary cancer model by MRI and in vitro and in vivo MR spectroscopyM E Pisanu, A Ricci, L Paris, et al.
International Journal of Cancer|November 3, 1995
Growth of ovarian-carcinoma cell lines at physiological folate concentration: effect on folate-binding protein expression in vitro and in vivoS Miotti, P Facheris, A Tomassetti, et al.
Hybridoma|February 1, 1988
Monoclonal antibodies against NIH 3T3 cells transformed by human thyroid carcinoma DNAR Alzani, M A Pierotti, S Ménard, et al.
British Journal of Cancer|October 1, 1995
In vitro and in vivo stability and anti-tumour efficacy of an anti-EGFR/anti-CD3 F(ab')2 bispecific monoclonal antibodyD R Negri, E Tosi, O Valota, et al.
British Journal of Cancer|November 28, 2013
Choline kinase-alpha by regulating cell aggressiveness and drug sensitivity is a potential druggable target for ovarian cancerA Granata, R Nicoletti, V Tinaglia, et al.
Bioconjugate Chemistry|May 20, 1998
Role of cross-linking agents in determining the biochemical and pharmacokinetic properties of Mgr6-clavin immunotoxinsF Dosio, S Arpicco, E Adobati, et al.
European Journal of Cancer (Oxford, England : 1990)|February 26, 2013
A single-chain fragment against prostate specific membrane antigen as a tool to build theranostic reagents for prostate cancerB Frigerio, G Fracasso, E Luison, et al.
Journal of Experimental & Clinical Cancer Research : CR|July 25, 2019
Anti-PSMA <sup>124</sup>I-scFvD2B as a new immuno-PET tool for prostate cancer: preclinical proof of principleB Frigerio, S Morlino, E Luison, et al.
Pageof 14

Showing results (111-120 of 131) with videos related to

Sort By:
Pageof 14
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
Radioimmunoscintigraphy of ovarian cancer with the MOv18 monoclonal antibodyF Crippa, G L Buraggi, E Di Re, et al.
Hybridoma|August 1, 1992
Production and characterization of a monoclonal antibody against the ribosome inactivating protein alpha sarcinA J Ferreri, E Ferraris di Celle, M Caldera, et al.
British Journal of Cancer|December 17, 2013
Monitoring response to cytostatic cisplatin in a HER2(+) ovary cancer model by MRI and in vitro and in vivo MR spectroscopyM E Pisanu, A Ricci, L Paris, et al.
International Journal of Cancer|November 3, 1995
Growth of ovarian-carcinoma cell lines at physiological folate concentration: effect on folate-binding protein expression in vitro and in vivoS Miotti, P Facheris, A Tomassetti, et al.
Hybridoma|February 1, 1988
Monoclonal antibodies against NIH 3T3 cells transformed by human thyroid carcinoma DNAR Alzani, M A Pierotti, S Ménard, et al.
British Journal of Cancer|October 1, 1995
In vitro and in vivo stability and anti-tumour efficacy of an anti-EGFR/anti-CD3 F(ab')2 bispecific monoclonal antibodyD R Negri, E Tosi, O Valota, et al.
British Journal of Cancer|November 28, 2013
Choline kinase-alpha by regulating cell aggressiveness and drug sensitivity is a potential druggable target for ovarian cancerA Granata, R Nicoletti, V Tinaglia, et al.
Bioconjugate Chemistry|May 20, 1998
Role of cross-linking agents in determining the biochemical and pharmacokinetic properties of Mgr6-clavin immunotoxinsF Dosio, S Arpicco, E Adobati, et al.
European Journal of Cancer (Oxford, England : 1990)|February 26, 2013
A single-chain fragment against prostate specific membrane antigen as a tool to build theranostic reagents for prostate cancerB Frigerio, G Fracasso, E Luison, et al.
Journal of Experimental & Clinical Cancer Research : CR|July 25, 2019
Anti-PSMA <sup>124</sup>I-scFvD2B as a new immuno-PET tool for prostate cancer: preclinical proof of principleB Frigerio, S Morlino, E Luison, et al.
Pageof 14